Dr. Theresa Matkovits Ph.D. serves as Chief Development Officer of the Company. Prior to joining Matinas, from May 2015 until October 2018, Dr. Theresa Matkovits held positions of increasing responsibility at ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), most recently serving as chief operating officer of ContraVir. From March 2013 to May 2015, Dr. Matkovits was the Research and Development Program Leader at NPS Pharmaceuticals (“NPS”). From 2010 to February 2013, Dr. Matkovits was Vice President, Innovation Leader for Infectious Disease at The Medicines Company. From 1997 to 2010, Dr. Matkovits served in various roles including Executive Director, Head of Strategic Planning and Operations for Novartis. She currently serves on the board of Aradigm Corporation (NASDAQ: ARDM), Appili Therapeutics, a privately held Canadian company focused on developing products to treat infectious disease and BioSurplus, Inc., a privately held company that buys and resells preowned lab equipment. Dr. Matkovits earned her Ph.D. in Biochemistry and Molecular Biology from the University of Medicine and Dentistry of NJ.
As the Chief Development Officer of Matinas Biopharma Inc, the total compensation of Theresa Matkovits at Matinas Biopharma Inc is $698,138. There are 4 executives at Matinas Biopharma Inc getting paid more, with Jerome Jabbour having the highest compensation of $1,325,180.
Theresa Matkovits is 52, he's been the Chief Development Officer of Matinas Biopharma Inc since 2018. There are 11 older and 5 younger executives at Matinas Biopharma Inc. The oldest executive at Matinas Biopharma Holdings Inc is Herbert Conrad, 87, who is the Independent Chairman of the Board.
Theresa's mailing address filed with the SEC is C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302, BEDMINSTER, NJ, 07921.
Over the last 8 years, insiders at Matinas Biopharma Inc have traded over $0 worth of Matinas Biopharma Inc stock and bought 1,157,037 units worth $1,139,222 . The most active insiders traders include Patrick G Lepore, Adam K Stern e James S Scibetta. On average, Matinas Biopharma Inc executives and independent directors trade stock every 40 days with the average trade being worth of $187,938. The most recent stock trade was executed by Adam K Stern on 21 August 2020, trading 20,000 units of MTNB stock currently worth $16,600.
matinas biopharma (nyse mkt: mtnb) is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. the company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. the company's lead drug candidate mat2203, currently in phase 2, is an orally-administered, encochleated formulation of amphotericin b (a broad spectrum fungicidal agent). the company has an open investigational new drug (ind) application for mat2501, currently in phase 1, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (ntm) and multi-drug resistant gram negative bacterial infections. the company's lead anti-infective product candidates, mat2203 and mat2501, position matinas biopharma to bec
Matinas Biopharma Inc executives and other stock owners filed with the SEC include: